Monte Rosa Therapeutics, Inc. Research And Development Expense

Quick Answer

Monte Rosa Therapeutics, Inc. reported Research And Development Expense of $141.50 million for the year ending 2025.

  • Monte Rosa Therapeutics, Inc. showed an increase of +16.4% in Research And Development Expense from 2024 to 2025.
  • This data is from Monte Rosa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), Monte Rosa Therapeutics, Inc.'s Research And Development Expense has grown by 489.5%.
  • Historical annual values: Fiscal year 2025: $141.50 million | Fiscal year 2024: $121.56 million | Fiscal year 2023: $111.27 million | Fiscal year 2022: $85.06 million | Fiscal year 2021: $57.16 million | Fiscal year 2020: $24.01 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: